Ceritinib
- Generic Name
- Ceritinib
- Brand Names
- Zykadia
- Drug Type
- Small Molecule
- Chemical Formula
- C28H36ClN5O3S
- CAS Number
- 1032900-25-6
- Unique Ingredient Identifier
- K418KG2GET
- Background
Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-as...
- Indication
Ceritinib is a kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib. This indication is approved under accelerated approval based on tumor response rate and duration of response. An improvement in survival or...
- Associated Conditions
- Refractory, locally advanced Non small cell lung cancer, Refractory, metastatic Non small cell lung cancer
- Associated Therapies
- -
Next Generation Personalized Neuroblastoma Therapy
- Conditions
- Interventions
- First Posted Date
- 2016-05-23
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Yael P Mosse
- Target Recruit Count
- 66
- Registration Number
- NCT02780128
- Locations
- 🇺🇸
The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
- First Posted Date
- 2016-04-06
- Last Posted Date
- 2019-10-10
- Lead Sponsor
- University of Washington
- Registration Number
- NCT02729961
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2018-04-02
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 4
- Registration Number
- NCT02638909
- Locations
- 🇺🇸
Yale University, Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Swedish Cancer Institute, Seattle, Washington, United States
🇺🇸University of Colorado Cancer Center, Aurora, Colorado, United States
Capmatinib, Ceritinib, Regorafenib, or Entrectinib in Treating Patients With BRAF/NRAS Wild-Type Stage III-IV Melanoma
- Conditions
- Interventions
- First Posted Date
- 2015-10-27
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 1
- Registration Number
- NCT02587650
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
- First Posted Date
- 2015-10-23
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 234
- Registration Number
- NCT02584933
- Locations
- 🇺🇸
Maryland Oncology Hematology P A, Rockville, Maryland, United States
🇺🇸Essex Oncology of North Jersey PA, Belleville, New Jersey, United States
🇨🇳Novartis Investigative Site, Taoyuan, Taiwan
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy
- Conditions
- Interventions
- First Posted Date
- 2015-09-24
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Giselle Sholler
- Target Recruit Count
- 500
- Registration Number
- NCT02559778
- Locations
- 🇺🇸
Penn State Milton S. Hershey Medical Center and Children's Hospital, Hershey, Pennsylvania, United States
🇺🇸St. Lukes, Boise, Idaho, United States
🇺🇸Connecticut Children's Hospital, Hartford, Connecticut, United States
Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2015-07-31
- Last Posted Date
- 2023-02-03
- Lead Sponsor
- University of Texas Southwestern Medical Center
- Target Recruit Count
- 14
- Registration Number
- NCT02513667
- Locations
- 🇺🇸
UT Southwestern Medical Center, Dallas, Texas, United States
A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors
- Conditions
- Interventions
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2020-12-19
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 33
- Registration Number
- NCT02422589
- Locations
- 🇺🇸
Cancer Therapy & Research Center UT Health Science Center SC-4, San Antonio, Texas, United States
🇺🇸Henry Ford Hospital SC, Detroit, Michigan, United States
🇺🇸Karmanos Cancer Institute Oncology Department, Detroit, Michigan, United States
Novartis PhII Ceritinib (LDK378) in R/R ALK+ Hem Malignancies
- First Posted Date
- 2015-01-22
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Anne Beaven, MD
- Registration Number
- NCT02343679
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
- First Posted Date
- 2015-01-13
- Last Posted Date
- 2020-04-21
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 156
- Registration Number
- NCT02336451
- Locations
- 🇺🇸
The Ohio State University Comprehensive Cancer Center Ohio State University, Columbus, Ohio, United States
🇺🇸USC Kenneth Norris Comprehensive Cancer Center SC-3, Los Angeles, California, United States
🇺🇸Dana Farber Cancer Institute SC-12, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.